Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Jasper Therapeutics, Inc./ SC TO-I

SEC Filing · SC TO-I

Jasper Therapeutics, Inc.

JSPRNASDAQEQUITYCurrent

SEC Filing

Filed Oct 7, 2026Accepted Oct 7, 2026, 7:50 AM EDTCIK 1788028Accession 0001213900-26-107397
View company →Permanent SEC source ↗
Share

Company context

Jasper is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The company is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant and mast cell mediated diseases such as chronic urticarias and allergic asthma. KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.

Current securities

JSPRNASDAQ · EQUITY · Current
Historical securities (4)
AMHCNASDAQ · EQUITY · Historical · closed Sep 27, 2021AMHCUNASDAQ · UNIT · Historical · closed Sep 24, 2021AMHCWNASDAQ · WARRANT · Historical · closed Sep 24, 2021JSPRWNASDAQ · WARRANT · Historical · closed Sep 24, 2026

Recent company filings

  1. PRE 14A filingOct 9, 2026
  2. Other EventsOct 7, 2026
  3. Submission of Matters to a Vote of Security HoldersOct 5, 2026
  4. Financial Statements and ExhibitsOct 5, 2026
  5. Financial Statements and ExhibitsOct 1, 2026

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.